Introduction.
Staphylococcus aureus is a significant cause of morbidity and mortality; methicillinresistant S. aureus (MRSA) caused an estimated 18,650 deaths in the United States in 2005 (19) . Antibiotic resistance continues to increase among S. aureus isolates including community-associated MRSA (7, 30) , healthcare-associated MRSA (12) , and S. aureus 5 with reduced susceptibility to vancomycin (20) . Understanding how this organism avoids host immune defenses is crucial for the development of new strategies to prevent and treat infections.
Complement is a major component of innate immunity and plays a vital role in the 10
control of many bacterial pathogens (28) including S. aureus (15, 21, 33) . Indeed this organism secretes several small soluble proteins that interfere with normal complement host defense mechanisms, including SCIN and Efb (15, 32) . We have previously shown that the human complement regulator factor I is captured on the S. aureus cell surface where it is activated and cleaves the crucial opsonin C3b (22) to iC3b (3) . This results in 15 decreased phagocytosis by human neutrophils (2) . We subsequently showed that the A domain of clumping factor A (ClfA), an important surface-located fibrinogen binding protein, bound factor I and acted as a cofactor to trigger cleavage of C3b to iC3b (13) .
The binding to fibrinogen by ClfA involves the C-terminus of the -chain binding to a 20 trench located between subdomains N2 and N3 by "dock-lock-latch" mechanism (18) .
Residues Pro336 and Tyr338 are located in the trench and are crucial for ligand bindinga P336S Y338A mutant (ClfAPYII) is completely defective in fibrinogen binding (23) .
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Clumping factor A is covalently anchored to the cell wall of S. aureus and promotes adhesion of the bacterium to fibrin clots and to thrombi created on heart valves in a rat model of endocarditis (25) . In addition, ClfA is required for survival of bacteria following injection into the blood stream of mice (16) . This was attributed to the ability 5 of the protein to promote bacterial resistance to phagocytosis by neutrophils. It was proposed that binding to fibrinogen prevented the deposition or recognition of opsonins.
However, phagocytosis experiments performed in the absence of fibrinogen demonstrated that the expression of ClfA still contributed an anti-phagocytic, suggesting the existence of another mechanism (14) . 10 In mouse models of S. aureus bacteremia and septic arthritis, bacteria expressing the nonfibrinogen binding mutant of ClfA were less virulent than a null mutant that was devoid of the surface protein (17) . It was difficult to explain these effects by the loss of fibrinogen binding alone. In the present study, we have analyzed the interaction of ClfA 15 with factor I on the bacterial cell surface and their roles in triggering cleavage of C3b to iC3b. In doing so, we have provided a novel explanation for the role of ClfA in disrupting opsonophagocytosis.
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Materials and Methods.
Bacteria and growth conditions. The S. aureus strains Newman or Reynolds were used in all experiments. Bacteria were grown in Columbia 2% NaCl broth at 37ºC to midlogarithmic phase, unless otherwise noted. Two ClfA-deficient strains that are isogenic mutants of strain Newman (9) were tested. ClfA-(2) denotes the isogenic mutant with the 5 genotype clfA2::Tn917 (21). ClfA-(5) denotes the isogenic mutant with a frame-shift mutation in clfA5 (11) . The ClfAPYII-expressing strain that expresses a non-fibrinogen binding variant of ClfA (ClfA P336A Y338S) (17) . Newman srtA::Tc r is a sortase Adeficient mutant (27) .
S. aureus strain Reynolds in mid-logarithmic phase produces undetectable 10 amounts of capsule by rocket immunoelectophoresis (4). To evaluate the role of capsule, a capsule-deficient isogenic mutant of Reynolds strain, JL022 (29) Serum, hirudin plasma, and factor I. Normal human serum (NHS) was obtained from the blood of healthy human volunteers in accordance with an Institutional Review Board approved protocol (Eastern Virginia Medical School IRB 02-06-EX-0216). The serum from 5 persons was pooled, aliquoted, and frozen at -80ºC, as previously described (4). 15
Heat-inactivated serum was generated by warming NHS to 56ºC for 30 minutes. Hirudin plasma was generated from the blood of human volunteers, as previously described (31) .
Hirudin plasma was used because it does not alter the function of the complement system unlike other methods of generating plasma like EDTA and heparin. Purified factor I was purchased commercially (CompTech, Tyler TX) and tested for purity and functionality 20 (3). C3-depleted serum was purchased commercially (CompTech).
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Cell wall preparations. Cell wall preparations were generated as previously described (13) . Briefly, S. aureus cell walls were digested with lysostaphin in a 30% raffinose buffer, to stabilize the bacterial protoplasts, containing protease inhibitors and DNAse.
The protoplasts were sedimented and the supernatant was recovered as the cell wall preparation. Detection of ClfA in cell wall preparations was performed by Western blot 5 analysis as previously described (13) .
Serum factor I binding to S. aureus. After washing, mid-logarithmic phase S. aureus were adjusted to a concentration of 1 × 10 9 bacteria per mL. Staphylococcal suspension (0.125mL) was added to 0.1 mL 60% DGVBS buffer and serum to achieve the described 10 final serum concentration and incubated for 5 minutes at 37° C. Bacteria were washed twice in GVBS --buffer and then boiled in 30µL of 2% SDS (0.05 M Tris) buffer for 5 minutes to remove surface bound proteins. Staphylococci were then sedimented and the supernatant recovered for analysis by factor I ELISA (below). Calculation of factor I expressed as molecules/CFU: 15 23 9 9 Factor I detection and quantitation. Factor I quantitation was performed by ELISA as previously described (13) . Briefly, ELISA plates were coated with goat anti-human factor I antibody (CompTech, Tyler, TX). Plates were blocked with 3% BSA in 20 PBS/Tween. Test samples were then incubated for 1 hour at room temperature. Factor I was detected with mouse monoclonal anti-human factor I antibody (Quidel, San Diego, at TRINITY COLLEGE on February 1, 2010 iai.asm.org Downloaded from CA) followed by goat anti-mouse horseradish peroxidase-linked antibody. Western blot detection of factor I was performed as previously described (13) . Briefly, the membrane was probed with a monoclonal anti-factor I antibody, a polyclonal goat anti-mouse-HRP antibody and then developed by ECL. A modified ELISA was used to quantitate factor I from NHS binding to rClfA. Wells of an ELISA plate were coated with 20 µg/ml of 5 either rClfA or rClfAPYII in carbonate buffer. Wells were washed, blocked, and then incubated with NHS in 3% BSA for 1 hour. Washed wells were then incubated with an anti-factor I monoclonal antibody followed by an anti-mouse HRP antibody as previously described.
10
Generation of iC3b in the presence of recombinant ClfA and ClfAPYII. In 100 µl of 60% DGVBS ++ , purified C3b (1 µg) and purified factor I (0.1 µg) were combined with rClfA or rClfAPYII (20, 100, or 200 µg) at 37°C for 16 hr. A control containing C3b, factor I, and factor H was used for these experiments. The samples were measured for iC3b generation by ELISA, as described elsewhere (2) . 15
Bacterial opsonization. S. aureus isolates were grown as described, washed with
GVBS
++ and diluted to a concentration of 1 × 10 9 CFU based on optical density at 600
nm. An aliquot of 1 × 10 8 CFU was incubated in 1% NHS in a total volume of 0.5 mL of GVBS ++ for 5 min. at 37° C. The bacteria were then washed twice with GVBS --. 20
Bacteria were also opsonized with C3b using purified complement components to activate the classical pathway as previously described (3) . Briefly, antibody-sensitized S.
aureus were successively incubated with purified complement components C1, C4, C2, at TRINITY COLLEGE on February 1, 2010 iai.asm.org Downloaded from and C3 to generate the classical pathway C3-convertase and bind C3b to the bacterial surface in the absence of other serum proteins. C3b-coated staphylococci were then incubated with factor I (4µg/mL) or factor H (4µg/mL) and factor I in GVBS --. C3-fragment detection and quantitation. Deposited C3-fragments were stripped from 5 bacteria with 25 mM methylamine as previously described (4). Measurement of iC3b was performed by ELISA using polyclonal anti-C3 antibody for capture and monoclonal anti-iC3b for detection, as previously described (2) . Total C3-fragments were measured by ELISA using different polyclonal anti-C3 antibodies for capture and detection, as previously described (2). C3-fragments were also analyzed by Western blot probing with 10 polyclonal anti-C3 antibody that recognizes the peptide chains of both C3b and iC3b, as previously described (5) . Images were captured digitally using Versadoc (BioRad).
Phagocytosis. Human neutrophils were prepared from heparinized human blood from healthy human volunteers by Hypaque-ficoll step gradient centrifugation, dextran 15 sedimentation, and hypotonic lysis. S. aureus isolates were grown, washed, and diluted as described above. An aliquot of 1 × 10 8 S. aureus was incubated in 1% NHS or 1%
heat-inactived serum in a total volume of 0.5 mL of GVBS ++ for 30 min. at 37°C. These were not washed, but instead an aliquot of 2 × 10 7 opsonized S. aureus was directly incubated with 1 × 10
Western blot detection of ClfA. The PVDF membrane was blocked in 3% BSA/TBST, which was also used for antibody diluents. The primary probe was a chicken anti-ClfA antibody (1:5000), the secondary probe was a goat anti-chicken HRP antibody (1:5000) (Genway Biotech Inc., San Diego, CA) and then the blot was developed by ECL. 
Results.
Factor I binding and C3b cleavage by S .aureus. Previously we have shown that the soluble A domain of ClfA can bind complement factor I and act as a cofactor (13) . In order to analyze the ability of ClfA expressed on the surface of S .aureus to promote 5 binding of factor I, the wild type ClfA+ strain Newman was compared with two null mutants lacking ClfA. Bacteria were incubated in human serum and factor I bound to the cells was stripped off by boiling cells in 2% SDS and measured by ELISA (Fig. 1A) . In 0.5% serum, the ClfA+ strain bound 112% more factor I than the mutants (mean value for the two null mutants; P = 0.012) whereas in 1% serum, the wild-type bound 69% 10 more factor I than the mutants (P = 0.012). These results show that expression of ClfA results in higher factor I binding compared to cells lacking the protein, but that some factor I still bound to the ClfA-mutants.
In order to evaluate the effect of ClfA on cleavage of C3b to iC3b on the S. aureus cell surface, the wild-type and ClfA-defective mutants were incubated in 1% NHS 15 for 5 minutes and the bound iC3b was stripped off using methylamine and measured by ELISA (Fig. 1B) . The level of iC3b on the ClfA+ strain was 125% higher than the mutants (mean value for the two mutants; P = 0.005). This showed that expression of ClfA increased the generation of iC3b, but that some C3 degradation occurred in the absence of ClfA. A decrease in iC3b was also detected by Western blotting analysis of 20 C3 fragments solubilized from the cell surface (Fig. 1C) .
Cleavage of C3b to iC3b on the S. aureus surface should decrease the number of alternative pathway C3-convertases on the bacterial surface and inhibit the deposition of at TRINITY COLLEGE on February 1, 2010 iai.asm.org Downloaded from additional C3b. Therefore, we tested the total amount of C3-fragments deposited by serum on the surface of the wild-type compared with a ClfA-null strain over 60 minutes (Fig. 1D ). The differences were most striking at 1 minute with the ClfA-null strain binding 9-fold more C3-fragments compared with the wild-type (P < 0.001). The difference in C3-fragment binding narrowed over time, but remained significant. Thus, 5 the presence of ClfA appears to correlate with an overall decrease in the deposition of C3-fragment opsonins.
In order to evaluate whether the residual factor I binding to the ClfA-null strains could be non-specific, we tested a sortase-null mutant (27) of S. aureus strain Newman (Fig. 1E) . The sortase-null mutant is unable to anchor any LPXTG-motif cell wall 10 associated proteins (24) . No significant difference in factor I binding was evident between the ClfA-null strain [ClfA- (2) ] and the sortase-null (Sortase-) strain (P = 0.17), suggesting that the non-ClfA-dependent factor I-binding is unrelated to covalently anchored surface proteins.
15
C3b cleavage and ClfAPYII. ClfAPYII is a ClfA mutant with substitutions at positions 336 and 338 (ClfA P336A Y338S) that does not bind fibrinogen (6), the primary function described for ClfA. In order to test the role of ClfAPYII in factor I cleavage of C3b to iC3b on the S. aureus surface, a mutant of Newman expressing ClfAPYII was incubated in 1% normal human serum, stripped of C3-fragments and iC3b 20 was measured by ELISA ( Fig. 2A) . The ClfAPYII expressing strain generated 57% less iC3b compared with wild-type (P = 0.02, based on absolute values). This suggested that at TRINITY COLLEGE on February 1, 2010 iai.asm.org Downloaded from the presence of ClfAPYII altered the ability of factor I in serum to cleave C3b to iC3b on the bacterial surface.
In order to further elucidate how the expression of ClfAPYII affects factor I cleavage of C3b to iC3b on the S. aureus surface, experiments were conducted using purified complement components. S. aureus strains expressing ClfAPYII or ClfA (wild-5 type) were incubated with purified components to activate the classical pathway and bind C3b to the bacterial surface (3). The C3b-coated bacteria were then incubated with purified factor I or both purified factor I and purified factor H, stripped of C3-fragments using methylamine and iC3b and total C3-fragments measured by ELISA (Fig. 2B) . The
ClfA-expressing (wild-type) strain incubated with factor I alone showed increased C3b 10 cleavage by iC3b/C3 ratio (P = 0.05) compared with control. However, the ClfAPYIIexpressing strain incubated with factor I alone showed no increase in C3b cleavage above control, suggesting that ClfAPYII could not act as a cofactor for factor I on the S. aureus surface. Curiously, when the C3b-coated ClfAPYII-expressing strain was exposed to both factor I and a strong cofactor, factor H, C3b cleavage was similar to control. This 15 suggests that ClfAPYII interaction with factor I on the S. aureus surface may inhibit the normal cofactor activity of factor H.
We then tested whether recombinant ClfAPYII would show differences in cofactor activity for factor I compared with recombinant ClfA. Recombinant ClfA and ClfAPYII were incubated with purified C3b and purified factor I and iC3b generation 20 was measured by ELISA (Fig. 2C) . In the presence of 200 µg of recombinant ClfAPYII, factor I produced 57% less iC3b compared with the same amount of recombinant ClfA (P at TRINITY COLLEGE on February 1, 2010 iai.asm.org Downloaded from = 0.01). These findings again suggest that ClfAPYII has diminished cofactor activity for factor I compared with wild-type ClfA.
Factor I binding to S. aureus expressing ClfAPYII and recombinant ClfAPYII. In order to test factor I binding on the bacterial surface, serum factor I binding to the S. 5 aureus expressing ClfAPYII was compared with the wild-type and ClfA-null strains.
The bacteria were incubated in serum, stripped of surface proteins by boiling in 2% SDS and factor I was measured by ELISA (Fig. 3A) . Minimal factor I could be detected in the stripped surface protein supernatant for the ClfAPYII-expressing strain and was 86% decreased compared with the ClfA-deficient strains (P < 0.03). This suggested that either 10 the factor I was not binding to the bacterial surface of the ClfAPYII-expressing strain or that factor I could not be stripped from the ClfAPYII strain.
In order to test these possibilities, we incubated both strains in purified factor I and then solubilized cell-wall proteins with lysostaphin (13) . The cell-wall preparations were analyzed by Western blotting and probed for factor I with anti-factor I antibody 15 (Fig. 3B) . The factor I content of the cell wall preparations was also measured by ELISA (Fig. 3C) . The Western blot analysis showed that factor I was present in the cell wall preparation of both organisms. The ELISA measured similar amounts of factor I in the cell wall preparations of the ClfAPYII-expressing S. aureus compared with the wild-type. This demonstrated that similar amounts factor I bound to the cell wall of the ClfAPYII-20 expressing strain, but could not be removed from the cell wall by boiling in 2% SDS, which readily removed factor I from the surface of the wild-type strain. These results suggested that ClfAPYII bound factor I, but the binding properties were altered compared to wild-type ClfA.
In order to evaluate further the binding of factor I to ClfAPYII, we then tested the binding of serum factor I to recombinant ClfA (rClfA) or recombinant ClfAPYII (rClfAPYII) in an ELISA-type assay (Fig. 3D) . Both rClfA and rClfAPYII bound serum 5 factor I with similar half-maximal binding values of 50nM showing that both forms bind serum factor I effectively.
Phagocytosis of S. aureus expressing ClfAPYII. In order to understand better the impact of ClfA on complement-mediated phagocytosis, ClfAPYII-expressing S. aureus 10 was compared with the wild-type and ClfA-null strains. The bacteria were incubated with 1% normal human serum (NHS) or heated serum without complement activity and then added to purified human neutrophils in a 20:1 ratio. Bacteria were stained with acridine orange and extracellular bacteria were quenched with crystal violet. With heat inactivated serum minimal phagocytosis occurred for each strain, whether evaluated as 15 the absolute number of bacteria phagocytized per 100 neutrophils (Fig. 4A) or as the percent of neutrophils phagocytizing bacteria (Fig. 4B) . In normal human serum, neutrophils phagocytized 3-fold more ClfAPYII-expressing S. aureus compared with wild-type (P < 0.01) and phagocytized 2-fold more ClfAPYII-expressing S. aureus compared with the ClfA-null strain (P = 0.01). More neutrophils ingested ClfAPYII-20 expressing bacteria than either the wild-type (P = 0.02) or the ClfA-null strain (P = 0.03).
Although a trend towards increased phagocytosis was noticed for the ClfA-null strain compared with wild-type, this did not reach statistical significance. These findings show In order to test if C3 or C3b was necessary for factor I binding to ClfA, recombinant ClfA was incubated with normal human serum or C3-depleted serum and factor I binding was measured by ELISA (Fig. 5B) . Serum factor I binding to rClfA was 15 not significantly different in the presence or the absence of C3 or C3b at 25% serum (P = 0.07), but in 50% serum, rClfA bound 16% less factor I in the presence of C3 compared with C3-deficient serum (P = 0.02). These findings suggest that C3 is not required for serum factor I binding to ClfA. mutant were compared. Bacteria were grown in conditions where capsule was expressed strongly (stationary phase) or poorly (mid logarithmic phase) (4). Similar levels of factor I bound to the two strains under both growth conditions (Fig. 6A , P = 0.17) suggesting that neither capsule expression nor the phase of growth significantly affected factor I binding. Control experiments showed that ClfA was expressed by bacteria in both phases 5 (Fig. 6B) .
Factor I binding to clinical isolates. To evaluate if factor I could bind to clinical
isolates of S. aureus, five strains from each of four categories (invasive CA-MRSA, noninvasive CA-MRSA, invasive MSSA, non-invasive MSSA) were incubated with serum, 10 surface proteins were stripped and factor I measured by ELISA (Fig. 7A ). All 20 strains bound factor I. A three-fold difference was found comparing the strains which bound the most factor I compared with those which bound the least. We calculated that approximately 60,000 molecules of factor I were bound on average to the S. aureus
isolates. These experiments demonstrate that all clinical strains of S. aureus bind factor I. 15
Control experiments showed that ClfA was expressed by all clinical strains; a representative blot is shown in figure 7B .
Clinical strains that bound the most factor I would be expected to cleave more effectively C3b to iC3b and limit opsonic C3-fragment deposition on the S. aureus surface by the alternative pathway, as shown in figure 1D . Neutrophil phagocytosis 20 experiments were performed with the two clinical strains that bound the most factor I and the two clinical strains which bound the least factor I (Fig. 7C) . A 1.6-fold increase in phagocytosis efficiency was found for clinical isolates that poorly bound factor I at TRINITY COLLEGE on February 1, 2010 iai.asm.org Downloaded from compared with strains that bound the most factor I (P = 0.003). These findings support the likely clinical relevance of an association between factor I binding and virulence.
Effect of fibrinogen on factor I binding to ClfA. In order to test whether the presence of fibrinogen interferes with factor I binding to ClfA, we compared factor I binding in 5 serum, where there is minimal fibrinogen, to plasma which has a physiological concentration of fibrinogen (Fig 8A) . Use of the anti-coagulant hirudin does not affect activation of complement as occurs in plasma stabilized with EDTA or heparin (1).
Factor I binding to wild-type (ClfA+) S. aureus was increased in both plasma preparations compared with serum (P  0.01). There was no difference in factor I 10 binding to the ClfA-null strain [ClfA- (2) ] in the plasma compared to serum (P  0.1).
These results suggest that the presence of fibrinogen increases factor I binding to wildtype S. aureus.
In order to test whether factor I bound to the S. aureus continued to cleave C3b to iC3b in the presence of a physiological concentration of fibrinogen (2-4 mg/mL), we 15 compared the generation of iC3b on the surface of bacteria incubated in NHS or hirudin plasma (Fig. 8B) . For the wild-type strain (ClfA+), there was no difference in iC3b generated on the bacterial surface in NHS compared to hirudin plasma (P = 0.63). This suggests that factor I functions normally on the S. aureus surface in the presence of physiologic fibrinogen. 20
The influence of fibrinogen was also tested using purified factor I and purified fibrinogen in a solid phase binding assay with immobilized rClfA (Fig. 8C ). Purified fibrinogen increased purified factor I binding to rClfA in a dose-dependent manner. This figure 5A where factor I binding to S. aureus was increased in plasma, suggesting that fibrinogen increases the association of factor I with ClfA.
We then tested if fibrinogen in plasma was associated detectably with factor I in a solid phase assay where factor I was captured from plasma with an immobilized 5 monoclonal anti-factor I antibody (Fig. 8D) . Factor I was readily captured from plasma, but no bound plasma fibrinogen was detected when probed with an anti-fibrinogen antibody. We also investigated whether fixing fibrinogen to a surface would cause binding by factor I (Fig. 8E) . Here an immobilized anti-fibrinogen antibody was used to capture fibrinogen from plasma and bound plasma factor I measured with an anti-factor I 10 antibody. No plasma factor I bound to the solid-phased plasma fibrinogen.
In order to clarify whether fibrinogen is required for ClfA binding to factor I, we performed a solid phase assay to capture factor I from serum followed by incubation with increasing concentrations of rClfA or rClfAPYII (Fig. 8F ). Wells were coated with antifactor I antibody to capture factor I from serum. After washing, rClfA or rClfAPYII were 15 added and binding was detected with anti-ClfA antibody. The rClfA or rClfAPYII bound to serum factor I dose-dependently with similar affinities suggesting that ClfA binding to serum factor I does not require fibrinogen.
Discussion.
The studies described in this paper show that ClfA expression on the surface of S. aureus is associated with increased binding by factor I from serum, increased cleavage of surface-bound C3b to iC3b, and decreased C3-fragment binding to the S. aureus surface.
We have previously shown that factor I-mediated cleavage of C3b to iC3b on the S. 5 aureus surface is associated with decreased phagocytosis by human neutrophils (2).
Taken together, these findings suggest that ClfA binding of serum factor I and the resultant C3b cleavage to iC3b on the S. aureus surface is a plausible mechanism contributing to S. aureus evasion of complement host defenses.
Previous studies have shown that ClfA P336A Y338S does not bind fibrinogen 10 (23) and that in mouse models of S. aureus bacteremia and septic arthritis a consistent virulence pattern is found with the ClfAPYII mutant being less virulent that the ClfA null mutant (17) . It is quite striking that complement-mediated phagocytosis of these strains shows a similar progression in that ClfAPYII-expressing S. aureus are more readily phagocytized than the ClfA-null or the wild-type strain. These differences in 15 complement-mediated phagocytosis can be at least partly explained by the failure of ClfAPYII to act as a cofactor for factor I-mediated cleavage of C3b to iC3b. ClfAPYII also appears to inhibit the cofactor activity of factor H. Thus, ClfA has an important interaction with the complement system that likely contributes to the differences in virulence found in vivo that could not be attributed to ClfA interaction with fibrinogen. 20
These findings support the hypothesis that factor I binding to ClfA results in C3b cleavage to iC3b on the S. aureus surface and contributes to immune evasion and virulence.
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The presence of fibrinogen at physiological concentrations increases factor I binding to the S. aureus surface, increases factor I binding to ClfA, and does not adversely affect the cleavage of C3b on the bacterial surface. Factor I in serum does not appear to require fibrinogen for binding to ClfA or ClfAPYII (the latter being a molecule that cannot bind fibrinogen). 5
Previous studies have suggested that upon binding the factor H-C3b complex, factor I undergoes a conformational change that enables it to cleave C3b (8, 10). We speculate that factor I may undergo a similar conformational change upon binding the fibrinogen-ClfA complex that enables it to cleave C3b. We also propose that the 'activating' conformational change for factor I does not occur upon binding to ClfAPYII. 10 Based on these data, we propose the model illustrated in figure 9 . The apo form of ClfA is shown with the latching peptide emanating from the C-terminus of the N3 domain unbound to the N2 domain. When the D domain of fibrinogen contacts ClfA and the gamma-chain peptide inserts into the ligand-binding trench, a conformational change occurs which results in the fibrinogen peptide being locked in place by the latching 15 peptide undergoing beta-strand complementation with two beta strands in N2. Factor I binds the fibrinogen-ClfA complex and undergoes a conformational change into an 'active' form that can cleave C3b to iC3b. ClfAPYII, in contrast, is unable to bind fibrinogen and remains in the apo form with the latching peptide free. Factor I is also able to bind ClfAPYII, but does not undergo a conformational change to an 'active' form. 20
Thus, factor I complexed with ClfAPYII is unable to cleave C3b to iC3b. The stronger binding of factor I to ClfAPYII could be due to local changes in conformation due to the amino acid substitutions. Phagocytosis efficiency for the two clinical isolates that bound the least factor I (M25 and S68) and the two clinical isolates that bound the most factor I (M32 and M2) (C).
Isolates were incubated with 1% serum for 30 minutes, to which were added purified human neutrophils for 45 minutes, then stained with acridine orange, quenched with 15 crystal violet and assayed by fluorescence microscopy. Data are the mean ± SE of 3 independent experiments. Purified factor I (10 ng/mL) binding to recombinant ClfA (rClfA) in an ELISA in the presence of increasing purified fibrinogen (C). Data are the mean ± SE of 6 independent experiments. Factor I was captured from increasing concentrations of plasma and probed for associated plasma fibrinogen by ELISA (D). Monoclonal anti-factor I was used to 5 capture plasma factor I (control fI) and bound plasma fibrinogen (pfibrinogen/captured fI) was detected with anti-fibrinogen antibody. Data are the mean ± SE of 3 independent experiments. Fibrinogen was captured from increasing concentrations of plasma and probed from associated plasma factor I by ELISA (E). Anti-fibrinogen antibody was used to capture plasma fibrinogen and bound plasma factor I (pfactor I/captured fg) was 10 detected with anti-factor I antibody. Data are the mean ± SE of 3 independent experiments. Serum factor I was captured with anti-factor I antibody and assayed for bound rClfA or rClfAPYII by ELISA (F). Increasing concentrations of rClfA or rClfAPYII were added and detected with anti-ClfA antibody. Data are the mean ± SE of 4 independent experiments. 15 Figure 9 . A scheme to the associations of factor I and fibrinogen with ClfA and ClfAPYII. Fibrinogen (Fg) binds to ClfA and enhances the binding of factor I which is then in an 'active' conformation and able to cleave C3b to iC3b. ClfAPYII, which is unable to bind fibrinogen, is also able to bind factor I, but the factor I is not in an 'active' 20 conformation and unable to cleave C3b to iC3b.
at TRINITY COLLEGE on February 1, 2010 
